Innoviva (INVA) Receivables - Net (2013 - 2026)
Innoviva's (INVA) quarterly Receivables - Net came in at $34.0 million in Q1 2026, up 103.95% YoY from $16.7 million in Q1 2025, and down 41.72% on a QoQ basis from $58.4 million in Q4 2025.
Innoviva (INVA) Receivables - Net (2013 - 2026) Analysis & Trends
Innoviva (INVA) has 7 years of Receivables - Net data on file, last reported at $34.0 million in Q1 2026.
- Quarterly Receivables - Net rose 103.95% year-over-year to $34.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.0 million (up 103.95% YoY) and the FY2025 annual result came in at $58.4 million, down 11.55% from the prior year.
- Receivables - Net declined to $34.0 million in Q1 2026, from $58.4 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $69.6 million in Q4 2023 to a low of $6.7 million in Q3 2022.
- A 5-year average of $41.6 million and a median of $54.7 million in 2022 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2023 — Receivables - Net surged 745.53% — and 2024, when it sank 76.56%.
- Tracing INVA's Receivables - Net over 5 years: stood at $54.7 million in 2022, then grew by 27.34% to $69.6 million in 2023, then retreated by 5.24% to $66.0 million in 2024, then decreased by 11.55% to $58.4 million in 2025, then tumbled by 41.72% to $34.0 million in 2026.
- The last three Receivables - Net figures came in at $34.0 million (Q1 2026), $58.4 million (Q4 2025), and $63.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.79 Mn |
| Jun 30, 2026 | 59.79 Mn |
| Mar 31, 2026 | 34.01 Mn |
| Mar 31, 2026 | 34.01 Mn |
| Dec 31, 2025 | 58.35 Mn |
| Dec 31, 2025 | 58.35 Mn |
| Sep 30, 2025 | 63.35 Mn |
| Sep 30, 2025 | 63.35 Mn |
| Jun 30, 2025 | 20.93 Mn |
| Jun 30, 2025 | 20.93 Mn |
| Mar 31, 2025 | 16.67 Mn |
| Mar 31, 2025 | 16.67 Mn |
| Dec 31, 2024 | 65.97 Mn |
| Dec 31, 2024 | 65.97 Mn |
| Sep 30, 2024 | 60.51 Mn |
| Sep 30, 2024 | 60.51 Mn |
| Jun 30, 2024 | 26.78 Mn |
| Jun 30, 2024 | 26.78 Mn |
| Mar 31, 2024 | 14.14 Mn |
| Mar 31, 2024 | 14.14 Mn |